Browse CCL3

Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Monokine with inflammatory and chemokinetic properties. Binds to CCR1, CCR4 and CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-alpha induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002278 eosinophil activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002447 eosinophil mediated immunity
GO:0002521 leukocyte differentiation
GO:0002548 monocyte chemotaxis
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006887 exocytosis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0008347 glial cell migration
GO:0008360 regulation of cell shape
GO:0009306 protein secretion
GO:0009636 response to toxic substance
GO:0010818 T cell chemotaxis
GO:0010959 regulation of metal ion transport
GO:0014808 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
GO:0019058 viral life cycle
GO:0019080 viral gene expression
GO:0019083 viral transcription
GO:0019233 sensory perception of pain
GO:0019722 calcium-mediated signaling
GO:0019932 second-messenger-mediated signaling
GO:0022604 regulation of cell morphogenesis
GO:0030099 myeloid cell differentiation
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030316 osteoclast differentiation
GO:0030335 positive regulation of cell migration
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031214 biomineral tissue development
GO:0031349 positive regulation of defense response
GO:0031644 regulation of neurological system process
GO:0031663 lipopolysaccharide-mediated signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032611 interleukin-1 beta production
GO:0032612 interleukin-1 production
GO:0032640 tumor necrosis factor production
GO:0032651 regulation of interleukin-1 beta production
GO:0032652 regulation of interleukin-1 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032731 positive regulation of interleukin-1 beta production
GO:0032732 positive regulation of interleukin-1 production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032897 negative regulation of viral transcription
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035747 natural killer cell chemotaxis
GO:0035821 modification of morphology or physiology of other organism
GO:0036230 granulocyte activation
GO:0036314 response to sterol
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0043270 positive regulation of ion transport
GO:0043299 leukocyte degranulation
GO:0043307 eosinophil activation
GO:0043308 eosinophil degranulation
GO:0043410 positive regulation of MAPK cascade
GO:0043491 protein kinase B signaling
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0043615 astrocyte cell migration
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0043921 modulation by host of viral transcription
GO:0043922 negative regulation by host of viral transcription
GO:0044033 multi-organism metabolic process
GO:0044057 regulation of system process
GO:0045055 regulated exocytosis
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045671 negative regulation of osteoclast differentiation
GO:0046782 regulation of viral transcription
GO:0048245 eosinophil chemotaxis
GO:0048246 macrophage chemotaxis
GO:0048247 lymphocyte chemotaxis
GO:0048525 negative regulation of viral process
GO:0050663 cytokine secretion
GO:0050701 interleukin-1 secretion
GO:0050702 interleukin-1 beta secretion
GO:0050704 regulation of interleukin-1 secretion
GO:0050706 regulation of interleukin-1 beta secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050716 positive regulation of interleukin-1 secretion
GO:0050718 positive regulation of interleukin-1 beta secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050792 regulation of viral process
GO:0050848 regulation of calcium-mediated signaling
GO:0050850 positive regulation of calcium-mediated signaling
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051047 positive regulation of secretion
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051222 positive regulation of protein transport
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051272 positive regulation of cellular component movement
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051402 neuron apoptotic process
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051702 interaction with symbiont
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0051851 modification by host of symbiont morphology or physiology
GO:0051896 regulation of protein kinase B signaling
GO:0051897 positive regulation of protein kinase B signaling
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0051930 regulation of sensory perception of pain
GO:0051931 regulation of sensory perception
GO:0052312 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 modulation by host of symbiont transcription
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0070098 chemokine-mediated signaling pathway
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070296 sarcoplasmic reticulum calcium ion transport
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070509 calcium ion import
GO:0070555 response to interleukin-1
GO:0070588 calcium ion transmembrane transport
GO:0070723 response to cholesterol
GO:0070838 divalent metal ion transport
GO:0070997 neuron death
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072676 lymphocyte migration
GO:0072677 eosinophil migration
GO:0072678 T cell migration
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097305 response to alcohol
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:0097553 calcium ion transmembrane import into cytosol
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1901623 regulation of lymphocyte chemotaxis
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902656 calcium ion import into cytosol
GO:1903514 calcium ion transport from endoplasmic reticulum to cytosol
GO:1903532 positive regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903900 regulation of viral life cycle
GO:1903901 negative regulation of viral life cycle
GO:1904951 positive regulation of establishment of protein localization
GO:1990266 neutrophil migration
GO:2000021 regulation of ion homeostasis
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000501 regulation of natural killer cell chemotaxis
GO:2000503 positive regulation of natural killer cell chemotaxis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004674 protein serine/threonine kinase activity
GO:0004697 protein kinase C activity
GO:0004698 calcium-dependent protein kinase C activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0008047 enzyme activator activity
GO:0009931 calcium-dependent protein serine/threonine kinase activity
GO:0010857 calcium-dependent protein kinase activity
GO:0016004 phospholipase activator activity
GO:0031726 CCR1 chemokine receptor binding
GO:0031730 CCR5 chemokine receptor binding
GO:0042056 chemoattractant activity
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
GO:0060229 lipase activator activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04620 Toll-like receptor signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCL3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26729864MelanomaPromote immunityVaccination with combination therapy uniquely restricted Th2-cytokine production by CD4 cells, relative to combination therapy alone, and enhanced IFNγ production by CD8 and CD4 cells. We observed an increase in MIP-1α (macrophage inflammatory protein-1α)/CCL3 [chemokine (C-C motif) ligand 3], MIP-1β/CCL4, RANTES (regulated on activation, normal T-cell expressed and excreted)/CCL5, and GM-CSF production by CD8 and CD4 T cells following treatment.
26056232Breast CarcinomaPromote immunityPulmonary metastasis of breast cancer cells is promoted by a distinct population of macrophages, metastasis-associated macrophages (MAMs), which originate from inflammatory monocytes (IMs) recruited by the CC-chemokine ligand 2 (CCL2). We demonstrate here that, through activation of the CCL2 receptor CCR2, the recruited MAMs secrete another chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR1 in macrophages reduces the number of lung metastasis foci, as well as the number of MAMs accumulated in tumor-challenged lung in mice.
27407095Cervical carcinomaPromote immunityIntravaginal treatment of IL7-Fc, but not native IL7, induces upregulation of chemokines (CXCL10, CCL3, CCL4, and CCL5), cytokines (IFNγ, TNFα, IL6, and IL1β), and an adhesion molecule (VCAM-1) in the genital tract, leading to the recruitment of several leukocytes, including CD4, CD8, γδ T cells, and dendritic cells.
27879269MelanomaPromote immunity (infiltration)Intratumoral basophils enhanced CD8+ T-cell infiltration via production of chemokines CCL3 and CCL4; antibody-based blocking of these chemokines inhibited CD8+ T-cell infiltration.
21480223Bladder CarcinomaInhibit immunityBoth myeloid cell subsets from cancer patients were highly activated and produced substantial amounts of proinflammatory chemokines/cytokines including CCL2, CCL3, CCL4, G-CSF, IL-8 and IL-6. We demonstrate that these highly activated inflammatory myeloid cells represent a source of multiple chemokines/cytokines and may contribute to inflammation and immune dysfunction in bladder cancer.
18645037HepatomaPromote immunityTumor-infiltrating DCs expressed chemokine receptors CCR1 and CCR5, and T cells and macrophages expressed CCL3, a ligand for CCR1 and CCR5. Thus, we provide definitive evidence indicating that CCR1 and CCR5 and their ligand CCL3 play a crucial role in the regulation of intratumoral DC accumulation and the subsequent establishment of tumor immunity following induction of tumor apoptosis by suicide genes.
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7670.0782
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4350.825
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.0020.452
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1570.878
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.260.859
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7050.725
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1460.788
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2590.816
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0520.965
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2750.249
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL3
Namechemokine (C-C motif) ligand 3
Aliases G0S19-1; LD78ALPHA; MIP-1-alpha; SCYA3; small inducible cytokine A3 (homologous to mouse Mip-1a); MIP1A; G0/ ......
Chromosomal Location17q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCL3.
ID Name Drug Type Targets #Targets
DB05364ROX-888Small MoleculeCCL31